Hikal Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Hikal Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Hikal were recently set by distinguished experts, with an average mark of Rp330.00. If it reached this goal, it would represent a potential upside of approximately 5.67% from the previous closing price in April, 2024. The high end is Rp330.00, and the low is Rp330.00. If you're considering investing in 524735 stock, it's important to look at its competitors too.
5.67% Upside
Hikal Fair Value Forecast for 2023 - 2025 - 2030
In the last five years, Hikal's Price has decreased by 100.00%, going from Rp152.60 to Rp0.00. In the next year, analysts believe that Fair Value will reach Rp166.91 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$733.51 | Buy/Sell | $636.99 | 14.18% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$131.20 | Buy/Sell | $130.51 | 8.61% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$159.62 | Buy/Sell | $178.42 | 16.53% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£119.88 | Buy/Sell | £165.99 | 35.93% |
Hikal Revenue Forecast for 2023 - 2025 - 2030
Hikal's Revenue has seen impressive growth In the last three years, rising from Rp15.07B to Rp20.23B – a growth of 34.22%. 0 analysts predict Hikal's Revenue will decrease by 9.27% in the next year, reaching Rp18.36B. By 2030, professionals predict that Hikal's Revenue will decrease by 8.24%, to Rp18.56B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.50 | Buy/Sell | CHF105.00 | 20.25% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF221.00 | Buy/Sell | CHF307.83 | 23.30% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.40 | Buy/Sell | $32.87 | 20.08% |
.jpg)
Hikal Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Hikal's Dividend per Share has decreased from Rp1.20 to Rp1.20 – a 0.00% drop. For the following year, the 1 analysts predict that Hikal's Dividend per Share will drop by 50.00%, reaching Rp0.60. In 2030, the professionals' prediction is that 524735's Dividend per Share will decrease by 33.14%, reaching Rp0.80.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.23€ | Buy/Sell | 102.80€ | 19.48% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.85 | Buy/Sell | $58.15 | 21.52% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.53 | Buy/Sell | £17.30 | 17.97% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.41k | Buy/Sell | Rp1.43k | 6.34% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.25k | Buy/Sell | Rp5.67k | -3.25% |
| DIVISLAB Stock Forecast | Divi's Laboratories | Hold |
18
|
Rp4.02k | Buy/Sell | Rp3.30k | -16.22% |
Hikal EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Hikal's EBITDA has decreased from Rp2.71B to Rp2.56B – a 5.57% drop! Analysts predict that Hikal's EBITDA will increase in the upcoming year, reaching Rp3.17B. This would represent an increase of 23.77%. Over the next six years, experts predict that Hikal's EBITDA will grow at a rate of 38.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 503806 Stock Forecast | SRF | Outperform |
17
|
Rp2.64k | Buy/Sell | Rp2.48k | -1.52% |
| AUROPHARMA Stock Forecast | Aurobindo Pharma | Outperform |
18
|
Rp1.13k | Buy/Sell | Rp1.09k | 3.95% |
| 523642 Stock Forecast | PI Industries | Outperform |
14
|
Rp3.77k | Buy/Sell | Rp4.07k | 8.15% |
Hikal EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Hikal has seen a decline in its EBIT, from Rp1.91B to Rp1.49B – a 22.05% decrease. In the next year, analysts believe that EBIT will reach Rp1.94B – an increase of 30.49%. For the next six years, the forecast is forEBIT to grow by 57.09%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COROMANDEL Stock Forecast | Coromandel International | Outperform |
18
|
Rp1.18k | Buy/Sell | Rp1.20k | 3.21% |
| 524208 Stock Forecast | Aarti Industries | Hold |
16
|
Rp749.30 | Buy/Sell | Rp530.15 | -14.32% |
| LAURUSLABS Stock Forecast | Laurus Labs | Hold |
18
|
Rp436.95 | Buy/Sell | Rp370.83 | -14.41% |
Hikal EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last five years, Hikal's EPS has decreased by 100.00%, going from Rp7.68 to Rp0.00. In the next year, analysts believe that EPS will reach Rp8.40 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500027 Stock Forecast | Atul Ltd | Underperform |
16
|
Rp5.93k | Buy/Sell | Rp6.05k | 0.61% |
| 524200 Stock Forecast | Vinati Organics | Hold |
16
|
Rp1.64k | Buy/Sell | Rp1.83k | 0.44% |
| 532504 Stock Forecast | Navin Fluorine International | Hold |
16
|
Rp3.31k | Buy/Sell | Rp3.95k | -3.28% |
.jpg)